RET rearrangement
|
NSCLC
|
RET rearrangement
|
NSCLC
|
cabozantinib tablet Sensitive: A2 - Guideline
|
cabozantinib tablet Sensitive: A2 - Guideline
|
RET rearrangement
|
NSCLC
|
RET rearrangement
|
NSCLC
|
vandetanib Sensitive: A2 - Guideline
|
vandetanib Sensitive: A2 - Guideline
|
RET rearrangement
|
NSCLC
|
RET rearrangement
|
NSCLC
|
selpercatinib Sensitive: A2 - Guideline
|
selpercatinib Sensitive: A2 - Guideline
|
RET rearrangement
|
NSCLC
|
RET rearrangement
|
NSCLC
|
pralsetinib Sensitive: A2 - Guideline
|
pralsetinib Sensitive: A2 - Guideline
|
RET rearrangement
|
NSCLC
|
RET rearrangement
|
NSCLC
|
alectinib Sensitive: C2 – Inclusion Criteria
|
alectinib Sensitive: C2 – Inclusion Criteria
|
RET rearrangement
|
NSCLC
|
RET rearrangement
|
NSCLC
|
sunitinib Sensitive: C2 – Inclusion Criteria
|
sunitinib Sensitive: C2 – Inclusion Criteria
|
RET rearrangement
|
NSCLC
|
RET rearrangement
|
NSCLC
|
selpercatinib + pralsetinib Sensitive: C3 – Early Trials
|
selpercatinib + pralsetinib Sensitive: C3 – Early Trials
|
RET rearrangement
|
LUAD
|
RET rearrangement
|
LUAD
|
cabozantinib tablet Sensitive: C3 – Early Trials
|
cabozantinib tablet Sensitive: C3 – Early Trials
|
RET rearrangement
|
Thyroid Gland Carcinoma
|
RET rearrangement
|
Thyroid Gland Carcinoma
|
selumetinib Sensitive: D – Preclinical
|
selumetinib Sensitive: D – Preclinical
|
RET rearrangement
|
Thyroid Gland Papillary Carcinoma
|
RET rearrangement
|
Thyroid Gland Papillary Carcinoma
|
MK-2206 Sensitive: D – Preclinical
|
MK-2206 Sensitive: D – Preclinical
|
RET rearrangement
|
Thyroid Gland Carcinoma
|
RET rearrangement
|
Thyroid Gland Carcinoma
|
AZD1480 Sensitive: D – Preclinical
|
AZD1480 Sensitive: D – Preclinical
|